An interventional study of FlowTriever in Pulmonary Embolism, sponsored by Northwell Health. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Northwell Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.
Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 135th largest by planned enrollment of the 166 interventional ones that give a count, is one of 9 that started in 2022, is one of 82 with no phase, reaches primary completion later than 22 of the 42 other live ones, and was the 183rd registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 21+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
Angiodynamics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 38 · Phase 4 21
First in 1999; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.
Median enrollment 142 across the 166 interventional studies, 286 across the 68 observational. Of the 169 that completed or were terminated, 76 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 236 have an industry lead sponsor. The 10 most frequent:
Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.
Northwell Health has 3 studies filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
17 of the studies in Pulmonary Embolism with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05591118Phase 3NYU Langone HealthPulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy | 2027-03-29 |
| NCT07213778Phase 3Regeneron PharmaceuticalsREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | 2027-05-17 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 236 studies in Pulmonary Embolism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is focused on investigating the efficacy and safety of the FlowTriever device to treat low-risk submassive pulmonary embolism.
In this study, patients that present with low-risk submassive pulmonary embolism with hemodynamic stability and with either positivity of cardiac biomarkers, or radiographic or echocardiographic evidence of right ventricular strain will be assigned to be treated with mechanical thrombectomy, which includes conscious sedation, via FlowTriever.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
I1. ≥ 18 years of age
I2. Clinical signs and symptoms of low-risk Intermediate pulmonary embolism defined per 2019 ESC Guidelines:
Only one of the following:
Troponin I > 51.4 ng/L (Northwell reference laboratory)
I3. sPESI score 0 or >1*
*Signs of RV dysfunction on Echo TTE or CTPA or elevated cardiac biomarker levels may be present, despite a calculation of sPESI 0.
I4. Echocardiogram, Computed Tomography Pulmonary Angiogram, or pulmonary angiographic evidence of proximal filing defect in at least one main, lobar, or segmental pulmonary artery with or without pulmonary infarction
I5. Hemodynamically stable
EXCLUSION CRITERIA
E1. Patients with active and severe COVID-19 infection (e.g. using ventilator, requiring hemodynamic support)
E2. Unable to anti-coagulate with heparin or alternative
E3. Known sensitivity to radiographic contrast agents that cannot be pre-treated
E4. \< 6 months
E5. Current participation in another study that may interfere with the patient's participation in this study.
E6. Inability to consent
E7. Patient is pregnant or plans to become pregnant within the next 6 months and/or currently breastfeeding.
E8. Subsegmental pulmonary embolism only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: FlowTriever
Mechanical thrombectomy for pulmonary embolism
Change in mMRC dyspnea score from
Time frame: Baseline (state at time of admission to hospital) to 30-day follow-up.
Change in Pulmonary Embolism Quality of Life Questionnaire (PEmbQOL)
Time frame: Procedure to 30-day, 3-month, and 6-month follow up.
Change in Six Minute Walk Test (6MWT) (distance covered in meters over 6 minutes)
Time frame: Pre-procedure to 30-day, 3-month, and 6-month follow up.
Echocardiogram Measurements: Change
Time frame: Pre-procedure to 30-day and 6-month follow up
Echocardiogram Measurements: Change
Time frame: From pre-procedure echocardiogram compared to 30-day and compared to 6-month follow up
ICU Length of Stay
Time spent in the Intensive Care Unit (ICU) for the length of the hospital visit.
Time frame: Length of index hospitalization, length of hospitalization median of 9.1 days, length of ICU stay median 3.1 per JNS
Hospital Duration
Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal
Device related death Device related bleeding Device related vascular injury Device related cardiac injury Clinical deterioration Rescue intervention
Time frame: From end of index hospitalization to 30 days post-procedure, whichever comes first
Change in hemodynamic measurements
Time frame: Before insertion of device during the procedure compared to 5 minutes after device is removed
Site Complications
Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal
Oxygen Requirement
Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal
All-cause Mortality
Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal
Bleeding Re-thrombosis Edema Pain
Time frame: From end of index hospitalization to 30 days post-procedure, whichever comes first
Started Jan 2022 (actual). Primary completion is estimated for Jul 2027, 65 months after the start.
Of 125 non-industry interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 65 months is above that.
Counting every sponsor, half of 150 studies reached it within 25 months; a quarter within 15 and three quarters within 51.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jul 2024 → Jul 2027 and completion Jul 2024 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.